Cocarboxylase, lyophilizate 50 mg 5 pcs

Cocarboxylase is a coenzyme of thiamine (vitamin B1), in the body is phosphorylated with the formation of mono-, di- and triphosphoric esters, is part of enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids.

The exogenous vitamin B1 (thiamine) must be metabolized by phosphorylation into cocarboxylase, the finished form of the coenzyme, to participate in these processes.

Please note that the properties of cocarboxylase are only partially adequate to those of thiamine; cocarboxylase is not used to prevent and treat hypo- and avitaminosis of B1.

Indications

Chronic circulatory failure

• Metabolic acidosis,
• hyperglycemic coma and acidosis in diabetes,
• .Hepatic and renal failure,
• respiratory acidosis in chronic, cardiopulmonary failure,
• respiratory failure,
• ischemic heart disease,
• myocardial infarction and postinfarction cardiosclerosis (as part of complex therapy), acute alcohol poisoning and chronic alcoholism;
• intoxication with foxglove drugs, barbiturates,
• intoxication in infectious diseases: diphtheria, scarlet fever, typhoid and paratyphoid (in complex therapy), peripheral neuritis.

.

Composition

1 ampoule (vial) with powder for preparation of solution for injection contains:

the active ingredient:

cocarboxylase hydrochloride 50 mg

.

How to take, the dosage

Cocarboxylase is administered intramuscularly.

The dose is determined individually, depending on the nature of the disease and the severity of the patient’s condition.

Adults: 50-100 mg/day, once, if necessary (diabetic coma) – repeatedly after 1-2 hours; in future a maintenance dose of 50 mg/day is given; in circulatory insufficiency 50 mg is administered 2 hours before application of foxglove drugs 2-3 times a day.

In children daily (in 1-2 doses): up to 3 months – 25 mg, from 4 months to 7 years – 25-50 mg, from 8 to 18 years – 50-100 mg

.

Interaction

Cocarboxylase enhances the effect of cardiac glycosides and improves their tolerance.

Special Instructions

Because of the presence of glycocholic acid as an adjuvant, during repeated and prolonged administration of the drug in patients with jaundice or severe cholestasis (changes in the values of laboratory liver function tests), liver function should be carefully monitored.

Deficiency of one or more vitamins should be corrected by administration of the missing vitamin. Cernevit does not contain vitamin K, which, if necessary, can be administered separately.

After dilution, the drug is stable at a temperature not exceeding 25°C for 24 hours, but it is recommended that the drug be used immediately after dilution or stored for no more than 24 hours at a temperature of 2°C to 8°C.

The effect on the ability to drive and operate machinery

As Cernevit is intended for patients receiving parenteral nutrition and who are in severe to moderate condition, the ability to drive and operate machinery has not been evaluated.

Contraindications

Hypersensitivity to the drug.

Overdose

In case of exceeding the dose prescribed by the doctor there may be symptoms of overdose in the form of: tachycardia; nausea; vomiting; headache; weakness; fatigue; muscle cramps; cardiovascular system disorders; allergic reactions; increased sweating; shortness of breath.

In case of symptoms of overdose the drug is withdrawn and mandatory symptomatic treatment is carried out.

.

Pregnancy use

There are no data on the safety of the drug when administered to pregnant women.

In view of the insufficient number of studies, the drug should not be prescribed to pregnant and lactating women.